Supernus PharmaceuticalsSUPN
About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Employees: 652
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
267% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $352K
1.94% more ownership
Funds ownership: 104.32% [Q1] → 106.26% (+1.94%) [Q2]
9% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 79
2% less funds holding
Funds holding: 247 [Q1] → 241 (-6) [Q2]
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
20% less capital invested
Capital invested by funds: $1.94B [Q1] → $1.56B (-$384M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler David Amsellem 65% 1-year accuracy 17 / 26 met price target | 7%upside $36 | Neutral Downgraded | 11 Sept 2024 |
Financial journalist opinion
Based on 4 articles about SUPN published over the past 30 days
